Rademikibart Demonstrates Improved Lung Function, Reduced Exacerbations in People with Eosinophilic-Driven Type 2 Asthma

©freshidea/AdobeStock

At the 2025 European Academy of Allergy and Clinical Immunology (EAACI) Congress, Connect Biopharma presented new data supporting the efficacy of rademikibart, a next-generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, in people with eosinophilic-driven type 2 asthma.

The data, derived from post-hoc analyses of the company’s phase 2b trial in moderate-to-severe asthma, demonstrated that rademikibart significantly improved pre-bronchodilator FEV₁ and reduced annualized asthma exacerbation rates (AAER), particularly in participants with elevated biomarkers of type 2 inflammation.

In participants with baseline eosinophil counts ≥150 or ≥300 cells/µL, rademikibart was associated with rapid and sustained improvements in lung function. A clinically meaningful increase in FEV₁ was observed at week 1 and maintained through 24 weeks of treatment. Improvements were greater in participants with elevated eosinophils compared to the overall study population.

Patient-reported asthma control, measured by changes in the Asthma Control Questionnaire-6 (ACQ-6), also improved substantially in these biomarker-defined subgroups. Fewer individuals in the rademikibart group reported high post-baseline eosinophil counts compared to published dupilumab data.

In another analysis, rademikibart treatment resulted in notable reductions in AAER among participants with type 2 inflammation:

• 63% reduction in patients with elevated eosinophils
• 69% reduction in patients with elevated fractional exhaled nitric oxide (FeNO ≥25 ppb)
• 74% reduction in patients with both elevated eosinophils and FeNO

These reductions suggest that rademikibart may be particularly beneficial for people with high eosinophilic and nitric oxide inflammation, both considered key drivers of type 2 asthma.

Rademikibart is currently being evaluated in the phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD. Topline data from these trials are expected in the first half of 2026.

“Building on the previously reported data from our Phase 2b asthma study, these analyses highlight rademikibart’s capability to not only rapidly deliver improvements in lung function, but also significantly reduce annualized asthma exacerbation rates, particularly in those with high eosinophil and fractional exhaled nitric oxide or FeNO counts, key markers of type 2 inflammation,” Barry Quart, PharmD, CEO and director of Connect Biopharma, said in a press release. “We believe these findings continue to bolster support for our rapid Phase 2 clinical development plan and we look forward to reporting topline data from our parallel Seabreeze STAT studies in the first half of 2026.”

Source: Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress. News release. Connect Biopharma. June 13, 2025. Accessed June 17, 2025. https://investors.connectbiopharm.com/news-releases/news-release-details/connect-biopharma-presents-data-supporting-rademikibart-european